Clinical Trials
30 trialsEnfortumab Vedotin and Pembrolizumab in People With Bladder Cancer
Memorial Sloan Kettering Cancer Center
Drug Screening Using IMD in Bladder Cancer
Brigham and Women's Hospital
A Study of Enfortumab Vedotin in People With Urothelial Carcinoma of the Upper Urinary Tract
Memorial Sloan Kettering Cancer Center
RECIPE-B1
Mayo Clinic
Cabozantinib in Combination With Enfortumab Vedotin for Locally Advanced or Metastatic Urothelial Cancer
Emory University
DEPECA-1 - A Phase II Study to Evaluate a First-line Systemic Therapy With Enfortumab Vedotin Plus Avelumab for Advanced and Metastatic Penile Carcinoma
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Precision Treatment of Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular Typing
Peking Union Medical College
Ph II Study of Enfortumab Vedotin in Patients With Advanced or Metastatic CRC or HCC
H. Lee Moffitt Cancer Center and Research Institute
A Study of Enfortumab Vedotin in People With Adenoid Cystic Carcinoma
Memorial Sloan Kettering Cancer Center
Enfortumab Vedotin Schedule De-escalation in Metastatic Urothelial Carcinoma
Fox Chase Cancer Center
N-803 in Combination With Pembrolizumab and Enfortumab Vedotin for Treatment of Urothelial Cancer
University of California, San Francisco
Enfortumab Vedotin With Radiation for Locally Advanced Bladder Cancer (CONSOLIDATE)
M.D. Anderson Cancer Center
Enfortumab Vedotin Plus Pembrolizumab With Selective Bladder Sparing for Treatment of Muscle-invasive Bladder Cancer
Hoosier Cancer Research Network
IMPROEV
Fox Chase Cancer Center
Enfortumab Vedotin and Pembrolizumab Combined With Radiotherapy in Muscle Invasive Bladder Cancer
University of California, San Francisco
SOGUG-PRINCIS
Spanish Oncology Genito-Urinary Group
ENCORE
University of Utah
Enfortumab Vedotin and Pembrolizumab With Cystectomy and/or Ureterectomy for Locally Advanced or Metastatic Bladder and Upper Urothelial Tract Cancer, CAST-AI Trial
Mayo Clinic
Pembrolizumab and Enfortumab Vedotin With Pembrolizumab Prior to and After Radical Nephroureterectomy for High-Risk Upper Tract Urothelial Cancer
Jonsson Comprehensive Cancer Center
Circulating Tumor DNA Response In Urothelial Cancer
University of Oklahoma
EV-4-EC
Medical College of Wisconsin
Chrono-EVP
British Columbia Cancer Agency
Renal Retention in High Grade Upper Tract Urothelial Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Enfortumab Vedotin for the Treatment of Patients With Metastatic or Unresectable Squamous Cell Carcinoma of the Penis
Mayo Clinic
PlugIN
Grupo Español Multidisciplinar de Melanoma
STAR-EV
University of Texas Southwestern Medical Center
REPRINT
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Pembrolizumab and EV With Radiation Therapy for MIBC Patients (PEVRAD)
Kyoto University Hospital
NEPTUNE
University of Michigan Rogel Cancer Center
Enfortumab Vedotin Plus Pembrolizumab for the Treatment of Locally Advanced or Metastatic Bladder Cancer of Variant Histology
Emory University